RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  2. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07502300, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer;

    Inclusion criterion 5

  3. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 8

    Use of immunomodulatory drugs within 14 days prior to the first dose of the study drug;

    Exclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    Inclusion criterion 4

  5. Must have at least one measurable lesion as defined by RECIST v1.1;

    Inclusion criterion 7

  6. Diagnosis of active malignancy within 3 years prior to study randomization;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07502300, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • Age ≥ 18 years;
  • Expected survival time ≥ 3 months;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Patients with histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer;
  • Agree to provide archived tumor tissue specimens from the primary or metastatic lesions within 3 years, or fresh tissue samples;
  • Must have at least one measurable lesion as defined by RECIST v1.1;
  • Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
  • No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%;
  • Organ function levels must meet the requirements;
  • Urinary protein ≤ 2+ or < 1000 mg/24h;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must be negative; patients must not be breastfeeding. All enrolled patients (regardless of male or female) must use adequate barrier contraception throughout the entire treatment period and for 6 months after the end of treatment.

Exclusion Criteria:

  • Pathology indicates small cell carcinoma containing non-small cell carcinoma components;
  • Patients who have previously received systemic treatment;
  • Previous treatment with ADC drugs where the small molecule toxin is a topoisomerase I inhibitor;
  • Use of immunomodulatory drugs within 14 days prior to the first dose of the study drug;
  • History of severe heart disease or cerebrovascular disease;
  • Receiving long-term systemic corticosteroid therapy at a dose >10 mg/day of prednisone or equivalent prior to the first dose;
  • Active autoimmune diseases and inflammatory diseases;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening;
  • Prolonged QT interval, complete left bundle branch block, etc.;
  • Diagnosis of active malignancy within 3 years prior to study randomization;
  • Hypertension inadequately controlled with two antihypertensive medications;
  • Poorly controlled diabetes mellitus;
  • History of interstitial lung disease (ILD)/pneumonitis requiring steroid therapy, etc.;
  • Concurrent pulmonary disease resulting in clinically severe impairment of respiratory function;
  • Patients with active central nervous system (CNS) metastases;
  • Severe infection within 4 weeks prior to study randomization;
  • Presence of large serous cavity effusions, or serous cavity effusions with symptoms, etc.;
  • Imaging findings indicating tumor invasion or encasement of major blood vessels in the abdomen, chest, neck, or pharynx;
  • Severe, non-healing wound, ulcer, or bone fracture within 4 weeks prior to signing informed consent;
  • Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
  • Patients with inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, intestinal obstruction, or chronic diarrhea;
  • History of allergy to recombinant humanized antibodies or any excipient component of BL-B01D1;
  • History of autologous or allogeneic stem cell transplantation;
  • Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection;
  • History of severe neurological or psychiatric disorders;
  • Receipt of other unapproved clinical study drugs or treatments within 4 weeks prior to study randomization;
  • Subjects planning to receive or having received live vaccines within 28 days prior to study randomization;
  • Other conditions deemed by the investigator to make the subject unsuitable for participation in this clinical trial due to complications or other circumstances.

Quoted from ClinicalTrials.gov, NCT07502300, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07502300, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07502300